Review Article

Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs

Table 4

miRNAs involved in chemoresistance in colorectal cancer treatments.

miRNATreatmentVerified targets in CRCReferences

miRNAs overexpressed in chemoresistance to conventional drugs
Let-7gS-1RAS, cyclin D, c-Myc, E2F, cytochrome c[177]
miR-10b5-FUBIM[178]
miR-19b5-FUSFPQ, MYBL2[179]
miR-20a5-FU, oxaliplatinBNIP2[180]
miR-23a5-FUAPAF-1[181]
miR-315-FU?[182]
miR-1405-FUHDAC[183]
miR-148a5-FU, oxaliplatin?[184]
miR-181bS-15-FURAS, cyclin D, c-Myc, E2F, cytochrome c[177]
miR192/2155-FUTYMS, DHFR[185, 186]
miR-203OxaliplatinATM[187]
miR-2245-FU?[188]
miR-520g5-FU, oxaliplatinCDKNIA (p21)[189]
miR-625-3pOxaliplatin?[190]

miRNAs downregulated in chemoresistance to conventional drugs
miR-225-FUBTG1[191]
miR-34a5-FUSIRT1, E2F3, KIT, LDHA[192ā€“194]
miR-1225-FUPKM2[195]
miR-1295-FUBCL2, TYMS, E2F3[196]
miR-133aOxaliplatinRFFL[197]
miR-139-5p5-FUNOTCH1[198]
miR-141/200cOxaliplatinZEB1[199]
miR-1435-FU, oxaliplatinBCL2, NFKB, ERK5, IGF1R[200, 201]
miR1455-FUFLI-1, RAD18[202, 203]
miR-1495-FUFOXM1[204]
miR-153OxaliplatinFOXO3[205]
miR-196aOxaliplatinHOXA7, HOXB8, HOXC8, HOXD8[206]
miR-200 cluster5-FUEMT-related genes[207]
miR2035-FUTYMS[208]
miR-2045-FUHMGA2[209]
miR-222OxaliplatinADAM17[188]
miR-297OxaliplatinABCC2[210]
miR-451IrinotecanABCC1[211]
miR-4975-FU, irinotecanIGF1R[212]
miR-519c5-FU, oxaliplatinABCG2, ELAVL1 (HuR)[213]
miR-1915OxaliplatinBCL2[214]

miRNAs overexpressed in chemoresistance to monoclonal antibody-based therapies
miR-17-3pCetuximab?[215]
miR-31Cetuximab?[216]
miR-126Bevacizumab, XELOX?[217]
miR-146-3pCetuximabIL1A[215]
miR-199a-5p/375CetuximabPHLPP1[218]
miR-486-5pCetuximabARHGAP5, ST5, DOCK3, TOB1, PIK3R1[215]

miRNAs downregulated in chemoresistance to monoclonal antibody-based therapies
Let-7 familyCetuximab, panitumumabKRAS[215, 219]
miR-7CetuximabEGFR, RAF1, ERK1/2, AKT[136]